PLCO筛查试验中游离PSA与临床显著及致死性前列腺癌的关系
在PLCO干预臂6727名男性中评估基线游离PSA百分比联合总PSA对临床显著前列腺癌和致死性前列腺癌的预测价值。中位随访19.7年,基线PSA≥2 ng/mL且游离PSA≤10的男性25年致死性前列腺癌累积发生率为6.1%。作者认为游离PSA应用于筛查风险分层并减少不必要的前列腺活检。
要点
- 基线PSA≥2 ng/mL且游离PSA≤10的男性15年和25年致死性前列腺癌累积发生率分别为3.2%和6.1%。
- 游离PSA>25%的男性15年和25年致死性前列腺癌累积发生率分别为0.03%和1.1%。
- 在55-64岁且基线PSA 2-10 ng/mL男性中,加入游离PSA百分比后临床显著前列腺癌C指数从0.56升至0.60,致死性前列腺癌从0.53升至0.64。
核心结论
- 在大型美国筛查试验中,基线PSA≥2 ng/mL的男性加用游离PSA百分比可改善临床显著前列腺癌和致死性前列腺癌的预测。
- 作者认为游离PSA应用于筛查风险分层并减少不必要的前列腺活检。
研究设计与样本
- PLCO(前列腺、肺、结直肠和卵巢癌筛查试验)干预臂中共6727名男性具有基线游离PSA百分比。
- 该队列中475例为临床显著前列腺癌,98例为致死性前列腺癌。
- 采用累积发生率和Cox分析评估游离PSA百分比/PSA与临床显著前列腺癌/致死性前列腺癌的关联,用Harrell C指数评估预测能力,Kaplan-Meier分析评估生存。
主要发现
- 中位随访19.7年,中位基线PSA为1.19 ng/mL,中位游离PSA百分比为18%。
- 基线PSA≥2 ng/mL且游离PSA≤10的男性15年和25年致死性前列腺癌累积发生率分别为3.2%和6.1%,而游离PSA>25%的男性分别为0.03%和1.1%。
- 在55-64岁且基线PSA 2-10 ng/mL的男性中,加入游离PSA百分比后临床显著前列腺癌C指数从0.56升至0.60,致死性前列腺癌从0.53升至0.64。
- 在65-74岁男性中,加入游离PSA百分比后临床显著前列腺癌C指数从0.60升至0.66,致死性前列腺癌无改善。
- 调整年龄、直肠指检、前列腺癌家族史和总PSA后,游离PSA百分比每降低1%与临床显著前列腺癌相关(HR 1.05,P < .001)。
临床怎么用
- 作者认为游离PSA应用于筛查风险分层并减少不必要的前列腺活检。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We studied whether adding percent free PSA to total PSA improves prediction of clinically significant prostate cancer and fatal prostate cancer. MATERIALS AND METHODS: A total of 6,727 men within the intervention arm of PLCO (Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial) had baseline percent free PSA. Of this cohort, 475 had clinically significant prostate cancer and 98 had fatal prostate cancer. Cumulative incidence and Cox analyses were conducted to evaluate the association between percent free PSA/PSA and clinically significant prostate cancer/fatal prostate cancer. Harrell's C index evaluated predictive ability. Kaplan-Meier analysis assessed survival. RESULTS: Median follow-up was 19.7 years, median baseline PSA was 1.19 ng/mL, median percent free PSA was 18%. Cumulative incidence of fatal prostate cancer for men with baseline PSA ≥2 ng/mL and percent free PSA ≤10 was 3.2% and 6.1% at 15 and 25 years, respectively, compared to 0.03% and 1.1% for men with percent free PSA >25%. In younger men (55-64 years) with baseline PSA 2-10 ng/mL, C index improved from 0.56 to 0.60 for clinically significant prostate cancer and from 0.53 to 0.64 for fatal prostate cancer with addition of percent free PSA. In older men (65-74 years), C index improved for clinically significant prostate cancer from 0.60 to 0.66, with no improvement in fatal prostate cancer. Adjusting for age, digital rectal exam, family history of prostate cancer, and total PSA, percent free PSA was associated with clinically significant prostate cancer (HR 1.05, P < .001) per 1% decrease. Percent free PSA improved prediction of clinically significant prostate cancer and fatal prostate cancer for all race groups. CONCLUSIONS: In a large U.S. screening trial, the addition of percent free PSA to total PSA in men with baseline PSA ≥2 ng/mL improved prediction of clinically significant prostate cancer and fatal prostate cancer. Free PSA should be used to risk-stratify screening and decrease unnecessary prostate biopsies.
引用
- Yim K, Ma C, Carlsson S, et al. Free PSA and Clinically Significant and Fatal Prostate Cancer in the PLCO Screening Trial. J Urol. 2023. PMID: 37384841. doi:10.1097/JU.0000000000003603
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。